Clover Health Investments, Corp. filings document the company’s Medicare Advantage insurance business, physician enablement technology, operating results, governance, and material events. Recent 8-K reports furnish earnings releases, guidance updates, Medicare Advantage enrollment information, Regulation FD presentations, and supplemental shareholder Q&A materials related to financial performance and business priorities.
Proxy materials cover annual meeting matters, board and governance disclosures, executive compensation, equity awards, and related stockholder voting items. Other current reports document officer transitions, principal financial and accounting officer appointments, compensatory arrangements, and formal disclosures connected to the company’s remote-first corporate structure and public-company reporting obligations.
Clover Health Investments, Corp. appointed Senator Robert G. Torricelli as a Class I director and Dr. Brian J. Miller, M.D., M.B.A., M.P.H., as a Class III director on September 22, 2026. Torricelli joins the Audit Committee, and Dr. Miller joins the Clinical Committee. The appointments fill two previously disclosed vacancies and bring the Board to nine directors.
For their 2026 service, each will receive a pro rata portion of the annual retainer and an RSU award covering shares with an RSU value of $200,000, prorated based on days of service from appointment through December 31, divided by 365 days. Torricelli has served as a director of the Company’s insurance subsidiaries since 2022; Dr. Miller serves on the Medicare Payment Advisory Commission and is vice chairman of the North Carolina State Health Plan Board of Trustees. Each will also enter into the Company’s standard form of indemnification agreement.
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) is the issuer named in former Officer Brady Priest’s notice of a proposed sale of 141,418 common shares, with an aggregate market value of $631,162.68; Morgan Stanley Smith Barney LLC is listed as broker. The notice also lists four sales during the prior three months: 215,291 shares on September 15, 2026, for $999,574.58 in gross proceeds; 73,516 shares on August 31, 2026, for $305,113.45; 474,801 shares on August 14, 2026, for $2,171,597.33; and 441,601 shares on August 7, 2026, for $2,141,988.87.
Clover Health Investments, Corp. (CLOV) executive Jamie L. Reynoso, CEO, Medicare Advantage, reported a sale of 1,921 shares of Class A Common Stock on September 17, 2026 at $4.56 per share in an open-market or private transaction, leaving 2,803,446 shares held directly. The sale was effected under a Rule 10b5-1 trading plan adopted on March 12, 2026.
Clover Health Investments, Corp. (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 3,170 shares of Class A Common Stock on September 16, 2026 at $4.64 per share. After this transaction, he held 275,897 shares directly.
The filing explains that these shares were sold to cover tax withholding obligations arising from the vesting of 6.25% of restricted stock units (RSUs) granted on June 16, 2025, under Clover Health’s equity incentive plans. The remaining RSUs vest quarterly in equal 6.25% installments through a final vesting date of June 16, 2029, subject to his continued service. The company states these are mandatory "sell to cover" transactions under its plan and do not represent discretionary trades. The filing also affirms the use of a Rule 10b5-1 trading plan for these sales.
Clover Health Investments, Corp. (CLOV) officer Jamie Reynoso filed a Rule 144 notice for a proposed sale of up to 1,921 shares of common stock through Morgan Stanley Smith Barney LLC on NASDAQ. The shares to be sold were acquired on September 15, 2026 as Restricted Stock Units from the issuer.
Reynoso also reports several sales of Clover Health common stock in the prior three months, including transactions on July 6, July 8, July 15, July 17, and September 15, 2026, some of which were executed as 10b5-1 sales.
Clover Health Investments, Corp. (CLOV) reports that officer Joseph Frank Oldakowski has filed a notice to sell 3,170 shares of Class A Common Stock under Rule 144 through Morgan Stanley Smith Barney LLC on September 16, 2026. The shares relate to vested restricted stock units and will be sold in a "sell to cover" transaction to satisfy tax withholding obligations, which the filing states are not discretionary trades by Oldakowski.
In the prior three months, Oldakowski reported sales of 12,102 shares of Class A Common Stock for $58,815.72 on June 16, 2026 under a 10b5-1 plan and 20,000 shares for $103,200 on September 14, 2026.
Clover Health Investments, Corp. (CLOV) reports that officer Wai Conrad, CEO of Counterpart Health, filed a Form 4 disclosing the sale of 300,000 shares of Class A common stock on September 15, 2026. The sale was executed at a weighted average price of $4.72 per share under a Rule 10b5-1 trading plan adopted on June 8, 2026, with individual trade prices ranging from $4.60 to $5.06. The shares sold were held indirectly in a family trust for which he serves as co-trustee; after the sale, that trust held 1,170,056 shares, and he also reported 1,065,699 shares held directly.
Clover Health Investments, Corp. (CLOV) reported that its Chief Legal Officer Karen Soares sold 6,846 shares of Class A common stock on September 15, 2026 at a weighted average price of $4.78 per share in sales mandated to cover tax withholding on the final vesting of 6.25% of restricted stock units granted September 15, 2022. These transactions were effected as a required "sell to cover" under the company’s equity incentive plans and are not discretionary trades; following the sale, Soares directly holds 1,607,371 shares of Class A common stock.
Clover Health Investments, Corp. (CLOV) reported that Jamie L. Reynoso, CEO, Medicare Advantage, sold 9,273 shares of Class A Common Stock on September 15, 2026 at a weighted average price of $4.78 per share. The footnotes state these mandated "sell to cover" transactions were executed under the issuer’s equity incentive plans to satisfy tax withholding on the vesting of the final 6.25% of restricted stock units originally granted on September 16, 2022 and do not represent discretionary trades. Following the sale, Reynoso directly holds 2,805,367 shares of Class A Common Stock.
Clover Health Investments, Corp. (CLOV) received a Form 144 notice that officer Karen M. Soares may sell 6,416 shares of Class A common stock on September 15, 2026 through Morgan Stanley Smith Barney LLC.
The shares come from restricted stock units vesting as compensation, and the sales are described as a “sell to cover” transaction solely to satisfy tax withholding obligations, not as discretionary trades.